Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
285
resultados
Última actualización
17/01/2026 [06:52:00]
Resultados 150 a 175 de 285
Resumen de: WO2026010379A1
The present invention relates to a pharmaceutical composition containing HER2-binding lipid nanoparticles loaded with mRNA encoding p53 protein. The so-called "p53 mRNA-loaded HER-binding lipid nanoparticles" developed in the present invention were verified to deliver p53 mRNA, a tumor inhibitor, which targets highly expressed HER2 in a "human epidermal growth factor receptor 2 (HER2)-positive cancer cell" model, and thus can induce cancer cell death without systemic toxicity.
Resumen de: WO2026009946A1
The purpose of the present invention is to provide: lipid nanoparticles useful as a nucleic acid delivery carrier; and a novel pH-sensitive cationic lipid for producing the lipid nanoparticles. The problem is solved by: a pH-sensitive cationic lipid comprising an asymmetric hydrocarbon chain; and lipid nanoparticles comprising the pH-sensitive cationic lipid as a constituent lipid.
Resumen de: US20260007738A1
The disclosure relates improved self-replicating RNA vectors e.g., for use as a RNA vaccine or therapeutic, and methods of use.
Resumen de: US20260007735A1
The present invention relates to a messenger RNA (mRNA)-based immunogenic composition that is capable of inducing a mammalian cell to produce an influenza virus-like particle (VLP). The immunogenic composition comprises one or more mRNAs encoding an influenza virus matrix 1 (M1) protein and one or more influenza virus hemagglutinin (HA) proteins and/or one or more influenza virus neuraminidase (NA) proteins.
Resumen de: US20260007737A1
The present disclosure provides for degradable lipid-polysaccharide-based cationic nanoparticles comprising an amino acid such as histidine or arginine conjugated to a C-2 carbon and a lipid conjugated to a C-6 carbon and methods of their use in the delivery of nucleic acids, polynucleotides, siRNA, and/or pDNA and/or hydrophobic drugs.
Resumen de: US20260007755A1
This invention relates to polymer drug conjugates according to formula I, and their use for treatment of diseases such as cancer.
Resumen de: US20260007741A1
Aspects of the present disclosure provides for improved vaccine compositions of ionizable lipid nanoparticles for the delivery of immunogenic nucleic acids to cells. Anionic phospholipids, including phosphatidylserine and phosphatidylglycerol are included in the lipid nanoparticles to increase the transfection efficiency in dendritic cells. In some embodiments, the incorporation of mono-unsaturated alkyl chain analogs in dimethylaminopropyl-dioxolane or heterocyclic ketal ionizable lipids in the formulation provided high levels of transfection in human dendritic cells, compared to other ionizable lipids in the same family, and demonstrated good stability to oxidative damage.
Resumen de: US20260007766A1
Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating muscle atrophy or myotonic dystrophy.
Resumen de: US20260007636A1
This document relates to methods and materials for treating vascular stenosis. For example, nanoparticles (e.g., poly lactic-co-glycolic acid (PLGA) nanoparticles) including one or more inhibitors of a monocyte chemoattractant protein (MCP) polypeptide (e.g., bindarit) are provided. In some cases, a composition (e.g., a hydrogel composition) including one or more nanoparticles including one or more inhibitors of a MCP polypeptide (e.g., bindarit) can be placed in direct contact with an adventitia of one or more blood vessels (e.g., one or more blood vessels at risk of stenosis formation) within a mammal (e.g., a mammal such as a human that underwent an angioplasty) to reduce or eliminate stenosis formation in the blood vessel(s).
Resumen de: WO2026008008A1
Disclosed herein are a lipid compound based on a biodegradable isocyanide or a biodegradable carboxylic acid terminal group, a preparation method therefor, and a use thereof in the preparation of a lipid compound for gene delivery. Further disclosed herein are a lipid compound for gene delivery, a preparation method therefor, and a use thereof in gene delivery. Further disclosed herein are a liposome and a lipid nanoparticle that comprise the lipid compound for gene delivery, and a gene delivery composition comprising the lipid compound, the liposome, or the lipid nanoparticle. The lipid compound for gene delivery, the liposome, the lipid nanoparticle, and the gene delivery composition herein enable more selective and efficient delivery and release of biomolecules, such as nucleic acids, in immune tissues and organs in vivo.
Resumen de: WO2026007911A1
Disclosed in the present invention are a novel carrier having the functions of inducing ferroptosis and delivering a nucleic acid drug, and use thereof in tumor treatment. The artesunate-protamine conjugate carrier of the present invention conjugates artesunate with protamine by means of an amide bond. The artesunate-protamine conjugate carrier prepared by the present invention has the characteristics of simple components and small toxic and side effects, and can induce ferroptosis of tumor cells. Moreover, said carrier has the function of delivering nucleic acids, and can be used for research in the anti-tumor field.
Resumen de: WO2026007662A1
The present invention relates to a material for local drug delivery and use thereof. Specifically provided is a nanoparticle composition. The nanoparticle composition comprises a cationic lipid, a PEG lipid, and a structural lipid, wherein the lipid component of the PEG lipid is 1.0-5.5 mol%, or a range between any two of the described values. The nanoparticle composition of the present invention is delivered only at the site of administration.
Resumen de: WO2026007297A1
A preparation method for a multifunctional biomimetic delivery platform efficiently crossing mucosal barriers and inducing mucosal immune enhancement and use thereof. The present invention relates to the technical field of biopharmaceuticals. On the basis of a biodegradable PLGA copolymer and a mixed lipid component, mucosal delivery carrier particles capable of simultaneously loading multiple antigens and immunostimulatory components are prepared by means of a double emulsion method, a rotary evaporation coating method, and an ultrasonic method. The PLGA nanoparticles are loading cores. The outer mixed lipid coating can fulfil the functions of mucus penetration, cell uptake, and thus immune activation.
Resumen de: US20260007615A1
The invention provides particles, compositions including the particles, and methods of making the particles using electrospray. In certain embodiments, the particles allow for high concentrations of a therapeutic or diagnostic agent to be delivered at low viscosity. Particles may also exhibit beneficial properties with respect to stability.
Resumen de: US20260007611A1
The present invention relates to an ultrasound-responsive nanocluster for cancer treatment and a method for manufacturing the same, the nanocluster according to the present invention has the advantage of efficiently delivering anticancer agents to cancer cells by promoting the release of the drug encapsulated within the nanocluster upon ultrasound treatment.
Resumen de: US20260007616A1
The invention relates to the development of a new pharmaceutical formulation for use as a medicament, in particular in anti-inflammatory diseases, and comprises of polymeric micro-/nanofibers incorporating echinochrome A. The composition provides increased stability and solubility, as well as controlled release for echinochrome A, while offering the potential for its targeted delivery.
Resumen de: US20260007600A1
Provided is an mRNA-liposome complex. The mRNA-liposome complex includes a liposome and a nucleic acid. The nucleic acid includes at least one mRNA encoding urate oxidase or recombinant urate oxidase. The liposome includes at least two lipids, and the at least two lipids include a core lipid. The liposome has a pKa ranging from 6.0 to 6.3. A molar percentage of the core lipid in a total molar amount of the liposome is not less than 15%.
Resumen de: US20260007601A1
A compound of Formula (I) or an N-oxide, a solvate, a pharmaceutically acceptable salt or a stereoisomer thereof is an ionizable cationic lipid compound.
Resumen de: WO2026007226A1
A nanoparticle loaded with an oral protein drug for the treatment of diabetes and a carrier. Raw materials of said nanoparticle comprise: a lipid molecule-modified zwitterionic polymer, a cationic lipid, a phospholipid, and cholesterol. The lipid molecule-modified zwitterionic polymer is composed of a lipid molecule and a polymer, wherein the lipid molecule is distearoyl phosphoethanolamine or dimyristoylglycerol, and the polymer is a poly(carboxybetaine) polymer, a poly(phosphobetaine) polymer, a poly(sulfobetaine) polymer, or poly-2-(N-oxide-N,N-diethylamino)ethyl methacrylate. Said nanoparticle significantly improves the oral bioavailability of the protein drug.
Resumen de: WO2026006906A1
A lipid nanoparticle delivery system; it has a cargo molecule; and a lipid nanoparticle encapsulating the cargo molecule, the lipid nanoparticle comprising ionizable lipids; helper lipids; sterol; and acid-containing lipids that are crosslinked; and methods of use thereof.
Resumen de: WO2026007157A1
The present invention relates to the synthesis of a peptide-based ionizable lipid and the use thereof, and specifically relates to an amino acid molecular building block with an alkylated side-chain primary amino group, a peptide-based ionizable lipid (PIL) formed therefrom, a method for synthesizing PIL, and a PIL library containing a plurality of PILs. The present invention further relates to a lipid nanoparticle (LNP) containing PIL, in particular a PIL-mediated organ-targeted LNP (PILOT LNP), a pharmaceutical composition containing same, and a targeted delivery method for administering the LNP or the pharmaceutical composition, or a method for preventing or treating a disease.
Resumen de: US2024423914A1
Compounds are provided having the following Formula (I):or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein G1, R1, R2, R3, L1, and L2 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.
Resumen de: WO2026009174A1
The present application discloses formulations comprising polyphenol- loaded phospholipid nanomicelles. The described phospholipid nanomicelles are loaded with resveratrol and/or rutin, which are particularly suitable for the delivery of these polyphenols. The formulations herein described is also suitable for skin diseases or conditions which can be prevented or treated with the administration of resveratrol and/or rutin.
Resumen de: WO2026008881A1
The present invention is in the field of medicine. More specifically, the present invention relates to extracellular vesicles, namely lipid nanoparticles that are conjugated to a biomolecule, namely an antibody or a nanobody, using a click reaction. Such extracellular vesicles can be applied for more effective treatment of diseases, in particular in vivo CAR T therapy, cardiac fibrosis and lysosomal storage diseases (LSD).
Nº publicación: JP2026500541A 07/01/2026
Solicitante:
サノフィパスツールインコーポレイテッド
Resumen de: CN120641393A
The present invention provides, in part, a diester and amide cationic lipid compound of formula (I): # imgabs0 # or a pharmaceutically acceptable salt thereof; a diester and amide cationic lipid compound of formula (II): # imgabs 1 # or a pharmaceutically acceptable salt thereof; a diester and amide cationic lipid compound of formula (III): # imgabs2 # (III), or a pharmaceutically acceptable salt thereof; and a diester and amide cationic lipid compound of formula (IV): # imgabs3 # or a pharmaceutically acceptable salt thereof. The compounds provided herein can be used to deliver and express mRNA and encoded proteins, for example, as components of liposomal delivery vehicles, and thus can be used to treat various diseases, disorders, and conditions, such as those associated with the lack of one or more proteins.
BOPI
Sede Electrónica
